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Background: Patients undergoing renal transplant procedures require multi-agent immunosuppressive regimens
both short term (induction phase) and long term (maintenance phase) to minimize the risk of organ rejection. There
are several drug classes and agents for immunosuppression. Use of these agents may increase the risk of different
harms including not only infections, but also malignancies including post-transplant lymphoproliferative disorder.
There is a need to identify which regimens minimize the risk of such outcomes. The objective of this systematic
review and network meta-analysis of randomized and observational studies is to explore whether certain modern
regimens of immunosuppression used to prevent organ rejection in renal transplant patients are associated with an
increased risk of post-transplant lymphoproliferative disorder and other malignancies.
Methods/design: ‘Modern’ regimens were defined to be those evaluated in controlled studies beginning in 1990
or later. An electronic literature search of Medline, Embase and the Cochrane Central Register of Controlled Trials
has been designed by an experienced information specialist and peer reviewed by a second information specialist.
Study selection and data collection will be performed by two reviewers. The outcomes of interest will include post-
transplant lymphoproliferative disorder and other incident forms of malignancy occurring in adult renal transplant
patients. Network meta-analyses of data from randomized and observational studies will be performed where
judged appropriate based on a review of the clinical and methodological features of included studies. A sequential
approach to meta-analysis will be used to combine data from different designs.
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Discussion: Our systematic review will include both single-agent and multi-agent modern pharmacotherapy regi-
mens in patients undergoing renal transplantation. It will synthesize malignancy outcomes. Our work will also add
to the development of methods for network meta-analysis across study designs to assess treatment safety.
Trial registration: PROSPERO Registration Number: CRD42013006951
Keywords: Renal transplant, malignancy, post-transplant lymphoproliferative disorder, systematic review, network
meta-analysisBackground
Kidney transplantation is the treatment of choice for
patients with end-stage kidney disease [1,2]. Patients
undergoing a renal transplant must be treated with im-
munosuppressive agents to prevent organ rejection.
These medications have different mechanisms of ac-
tion [3], but in some way disrupt the interaction and/
or stimulation of the antigen-presenting cells or T-
lymphocytes of the human immune system. Immuno-
suppression for renal transplantation includes both an
induction phase and a maintenance phase [3]. Induc-
tion involves the use of one of many medications such
as an anti-IL2 receptor antagonist (basiliximab or daclizu-
mab), a polyclonal anti-T-cell antibody (e.g. anti-thymocyte
globulin) or a monoclonal anti-T-cell antibody (e.g. anti-
CD52, alemtuzumab, anti-CD3 or OKT3). The mainten-
ance phase often involves two or three medications in
combination, but may also be a single agent. Possible
agents include calcineurin inhibitors (cyclosporin or ta-
crolimus), anti-metabolite agents (azathioprine, myco-
phenolate mofetil or mycophenolate sodium), steroids
(prednisone), co-stimulation blocker (belatacept) and/
or mammalian target of rapamycin inhibitors (sirolimus
or everolimus) [4].
Immunosuppressive agents are associated with un-
desired outcomes, including infection and malignancy
[5-9]. Of particular concern is a specific transplant-
related cancer referred to as post-transplant lymphoprolif-
erative disorder (PTLD), which has a one-year mortality
rate as high as 40% [10]. A recent editorial noted a
clear need to determine which immunosuppressant
combinations minimize the occurrence of PTLD, as the
types of drugs used for the induction and maintenance
phases play a role in the rate and types of cancers seen
[10-12]. From 2001 to 2010, 10,795 kidney transplants
were performed in Canada, and there are currently
16,164 Canadians alive with a functioning renal trans-
plant taking immunosuppressive agents [13]. Patients
receiving immunosuppressive drugs following renal
transplant are at an increased risk of cancers that
shorten survival, reduce quality of life and have high
treatment costs. It is important to determine if there
are specific regimens that can minimize the risk of
PTLD and other cancers.Network meta-analysis [14-16] is a statistical approach
used to compare different treatment regimens when
there is both direct and indirect information. Our sys-
tematic review and network meta-analyses will compare
the rates of PTLD and other cancers across the available
regimens.
Methods/design
Research question and selection criteria
Our systematic review will address the following re-
search question: In adults undergoing renal transplant-
ation, is there evidence of an association between certain
immunosuppressive regimens used in the induction and
maintenance phases and the risk of PTLD and other
cancers? The following criteria, summarized in the
Population – Interventions/Comparators – Outcomes –
Study design (PICOS) format, summarize the planned
selection criteria for this review.
Population
The review will include data from both male and female
adult patients who underwent a renal transplant. Pa-
tients who underwent either a first-time or repeat trans-
plantation are eligible for inclusion.
Intervention and comparators
The pharmacologic agents of relevance to this review
are summarized in Table 1. It is anticipated that the ma-
jority of studies will involve combinations of these
agents; however, monotherapy studies will also be in-
cluded. Studies of steroid avoidance and withdrawal will
also be included. It is possible that we will encounter
comparisons involving the same pharmacologic agents
but at varied doses across studies. Should this occur,
clinical experts will be consulted to determine the extent
to which such variations warrant ‘lumping’ into the same
treatment node within our network. In addition to
agent/combination level analyses, broader analyses of
regimens such as regimens with ‘induction vs no induc-
tion’ and ‘depleting vs non-depleting’ may also be ex-
plored if feasible, as well as analyses related to the
intensity of immunosuppression (related to both dose
and duration of treatment). To maximize clinical rele-
vance as well as clinical homogeneity between studies,
Table 1 Summary of agents for consideration in the planned systematic review









Alemtuzumab Campath, MabCampath, Campath-1H, Lemtrada
Muromonab-CD3 Orthoclone OKT3
Calcineurin inhibitors
Cyclosporin Neoral, Sandimmune, Restasis, CyA-NOF, CsA-Neoral, CsANeoral
Tacrolimus Prograf, Advagraf, Protopic, fujimycin, Advagraf, modigraf, LCP-tacro, Tsukubaenolide
Anti-metabolite agents















Prednisone Adasone, Ancortone, Apo-prednisone, Bicortone, Cartancyl, Colisone, Cortan, Cortancyl, Cortidelt, Cotone, Cutason, Dacorten,
Dacortin, Decortancyl, Decortin, Decortisyl, dehydrocortisone, Dekortin, Dellacort, Deltacortene, Deltacortene, Deltacortisone,
Delta-cortisone, Deltacortone, Deltasone, Deltra, Di-adreson, DiAdreson, Econosone, Enkorton, Enkortolon, Fernisone, Fiasone,
Hostacortin, IN-Sone, Incocortyl, Juvason, Kortancyl, Lisacort, Lodotra, Lodtra, Me-Korti, Metacortandracin, Meticorten, Nisona,
Nizon, Novoprednisone, Nurison, Orasone, Panafcort, Panasol, Paracort, Parmenison, Pehacort, Predeltin, Prednicen-M, Predni-
corm, Prednicort, Prednicot, Prednidib, Prednilonga, Predniment, predni tablinen, Prednitone, Prednizon, Prednovister, Presone,
Pronison, Rayos, Rectodelt, Retrocortine, SK-Prednisone, Servisone, Sone, Sterapred, Supercortil, Winpred, Wojtab, Zenadrid
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the year in which mycophenolate mofetil (CellCept) and
tacrolimus (Prograf) began to be commonly combined
in immunosuppression regimens, reflecting a significant
change of treatment. This change is associated with sig-
nificant changes in the approach to immunosuppression
since there were corresponding changes in patient char-
acteristics (including age, race and other factors such as
human leukocyte antigen (HLA) mismatch status and
co-interventions administered), which could have an im-
portant impact on the risk of malignancies.Outcomes
Studies will be considered as eligible if they report on
the occurrence of at least one of the following outcomes:
PTLD, non-melanoma skin cancer (i.e. squamous celland basal cell carcinoma) or other cancers (breast, colon,
lung, etc.).
Study design
Both randomized controlled trials (RCTs) and observa-
tional studies will be sought. Reasons for inclusion of
both designs are related to both the known limitations
of evaluating rare outcomes such as harms based on
only RCT data [17-21], and because relevant observa-
tional data are available. Recent literature has addressed
the value of observational studies to the field of nephrol-
ogy in addressing several types of issues that RCTs
cannot, such as safety issues [22]. We will include obser-
vational studies that have enrolled a minimum of 100
patients per treatment group and which (a) use propen-
sity matching techniques to minimize the risk of residual
confounding or (b) adjust for a minimum of two of the
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justed odds ratio: patient age, smoking status, history of
previous cancers, and sun exposure or region of resi-
dence (e.g. southern vs northern hemisphere). Studies
identifying patients for inclusion based on outcome sta-
tus will not be eligible. Our objective in selecting obser-
vational studies meeting these criteria is to incorporate
additional relevant research while seeking those which
may be associated with a smaller risk of residual con-
founding from selection bias.Electronic literature search
The literature search strategy has been developed in
consultation with a senior information specialist, who
received detailed input from the research team. The
strategy has been peer reviewed by a second information
specialist using the PRESS criteria [23]. A search for
RCTs and observational studies was subsequently de-
signed for Medline (1998 to the present), Embase (1998
to the present) and the Cochrane Library. Additional
file 1: Table S1 presents the Medline search strategy.
Studies will be limited to those published in English,
and only published reports will be included.Study selection, data collection and risk of bias
assessment
Stage 1 screening (i.e. titles and abstracts) will be per-
formed using a liberal accelerated approach, while Stage 2
screening of potentially relevant full text articles will be
conducted by two reviewers. Two reviewers will also ex-
tract data and assess risk of bias for all studies. Where ne-
cessary, a third party will be consulted if disagreements
cannot be resolved by discussion amongst the two re-
viewers with regard to either study selection or data col-
lection. The literature selection process will be presented
using a PRISMA flow diagram, and the PRISMA state-
ment will be used to guide the reporting structure [24].
A structured electronic data collection form will be de-
signed and implemented, and it will then be piloted and
used by two data collectors. We will collect extensive
study-level information including study design; publication
characteristics (author, journal, year and so forth); patient
inclusion/exclusion criteria; patient demographics of im-
portance to determine the clinical similarity of populations
across studies (mean age, gender distribution, prior trans-
plant history, ethnicity, malignancy history, smoking status
and the presence of viruses such as the Epstein-Barr virus
(EBV), cytomegalovirus, hepatitis B and C viruses, HIV
and human T lymphotropic virus); detailed intervention
information (agents, doses and duration/frequency of ad-
ministration, etc.); all clinical outcomes of interest as de-
scribed previously and risk of bias evaluations. RCTs will
be assessed using the Cochrane Risk of Bias tool, andobservational studies will be assessed using the Newcastle
Ottawa Scale.
Bias adjustments of observational evidence
The primary bias of interest from observational studies is
selection bias, a consequence of how clinicians choose an
immunosuppression regimen for their patients, which is
based primarily upon a patient’s immunologic risk. For ex-
ample, higher risk subjects may be given more potent im-
munosuppression regimens. The risk for organ rejection is
determined by the patient’s race, age, sensitization (amount
of antibody against anti-human leukocyte antigens) and
whether this was the first or a repeat transplantation. The
literature suggests that increased age, increased sun expos-
ure and EBV-positive donor organs being transplanted in
EBV-negative recipients all increase the risk of malignancy
[25-29]. As a result, we may encounter studies where pa-
tients in specific intervention groups are more susceptible
to malignancies as a result of particular characteristics that
are unbalanced between intervention groups (this may also
be associated with other unknown confounder imbalances
between groups). Methods to assess this adjustment factor
are outlined briefly in the analysis section below. Briefly,
tables of patient demographic information will be pre-
sented to clinical experts in a blinded fashion, who will as-
sess potential selection bias in the included observational
studies, which may reflect important differences in the risk
of malignancy between intervention groups for each study.
This will be done so that the clinicians can judge the low-
est and highest perceived differences in the risk of PTLD
and other cancers between intervention groups based on
differences in baseline characteristics between the patients.
Several authors have commented on the need to explore
the combination of data across study designs to explore
the comparative safety of medical interventions [30-33],
and discussions of bias adjustments in meta-analysis have
been presented by authors including Eddy et al. [34-36],
Sutton and Abrams [37], Greenland and Kheifets [38],
Turner et al. [39], Wolpert and Mengersen [40], Welton
and co-workers [41], Dominici et al. [42] and others.
Approach to data analysis
Our approach will be sequential: network meta-analyses
will first be performed using RCT data only. The second
step will then combine information from randomized
and observational studies without bias adjustments. Step
3 will then repeat the analysis from step 2 while incorp-
orating the input of bias adjustments provided by the
clinical experts. This approach will allow readers to ob-
serve the effect of each step on our findings, and will
also allow them to draw their own conclusions based on
their preferred level of evidence.
A Bayesian approach will be implemented in WinBUGS
(Version 1.4.3, MRC Biostatistics Unit, Cambridge, UK)
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allowing the data to drive the final inferences. The out-
comes relating to PTLD and cancers will be treated as bin-
ary outcomes in primary analyses; however, an approach
accounting for variations in person-time and exposure
time will be adopted if the duration of follow-up is found
to vary substantially from study to study.
Schmitz et al. [44] have suggested an approach to
combine data from different designs while considering
the effect of bias through the down-weighting of obser-
vational evidence. We will build on this approach by in-
corporating our derived study-specific accounts for bias,
which will appropriately increase the uncertainty of esti-
mates from observational studies and adjust for any
biases identified by expert opinion. To derive these as-
sessments, for each study we will: (i) present blinded
demographic tables stratified by intervention group to
the evaluating clinical expert; (ii) ask the expert whether,
based on his or her own expertise, one intervention
group appears to be at greater risk of malignancy than
the others based on these demographics, and if yes,
why?; (iii) ask the expert what he or she feels is the smal-
lest and the largest percentage difference in the occur-
rence of malignancy that might be due to the imbalance
in patient demographics. These values will populate
minimum and maximum values of bias adjustment fac-
tors in our sensitivity analyses, which will be drawn from
uniform distributions. We will transparently report the
experts’ rationale for bias judgments for all studies in
our completed review.
All results from network meta-analyses will be reported
with point estimates and corresponding 95% credible in-
tervals. The ranking/probability profile of each therapy,
the probability of each odds ratio being larger than 1 and
the probability of a therapy being associated with the low-
est risk of harm will be estimated. Model convergence will
be assessed by trace plots and the Brooks-Gelman-Rubin
statistic. Three chains will be fit in WinBUGS for each
analysis. We will explore model fit and compare alterna-
tive models by reviewing the residual deviance and the de-
viance information criteria from each model. We will look
for any statistical inconsistency in the findings from direct
and indirect evidence by fitting inconsistency models as
described elsewhere [45].
Supplemental and sensitivity analyses and exploration of
heterogeneity
Our sequential approach will allow an assessment of the
degree to which estimates vary between randomized and
observational studies. We will also use meta-regression
and subgroup analyses, if sufficient information is avail-
able at the study level. Possible covariates will include
year when the study was published, mean patient age,
EBV status, race and cytomegalovirus status.Reporting findings
We will summarize our estimates using appropriate graphs
and tables, along with a layperson’s summary. This will in-
clude the following: network diagrams showing the avail-
ability of evidence for all possible treatment comparisons;
summary point estimates and 95% credible intervals for all
pairwise comparisons, both in tabular form and in league
tables; and estimates of probabilities that each therapy is
deemed ‘best’ for each outcome along with associated aver-
age rankings of efficacy and safety [46]. We will also
present clear summaries of any deviations from our pri-
mary findings that are derived from our planned subgroup
and sensitivity analyses.Discussion
What this review will add to the field
The risks of PTLD and other malignancies faced by renal
transplant patients as a consequence of the medications
needed to minimize the risk of organ rejection are import-
ant to both patients and clinicians. We identified no prior
systematic review comparing the many possible immuno-
suppression treatments for kidney transplant patients with
regard to the occurrence of these outcomes. Our review
will provide a comprehensive source of information in the
published literature addressing this issue. From a meth-
odological perspective, there are currently few network
meta-analyses combining randomized and observational
studies for assessing treatment safety [33]. There is a re-
cent report [44] describing down-weighting methods but
it does not appear to address bias at the individual study
level. We intend that our review will expand on these
methods by incorporating bias adjustments of observa-
tional studies assessed at the study level.Challenges to the planned review
First, the inclusion of observational studies in meta-
analyses has long been debated given concerns of re-
sidual confounding in this class of studies. Our review
will attempt to address this concern by including only
those studies where an effort has been made to reduce
this risk, and we will also employ a framework to try to
minimize the effect of any remaining confounding in
our analyses. Second, the issue of intensity of immuno-
suppression is an important one that may influence the
risk of PTLD and other cancers; the extent to which in-
tensity can be truly established at the patient level within
the included studies is unclear at this time and will
require further exploration of the included studies to
determine. Third, renal transplantation is just one indi-
cation for PTLD and cancers resulting from immuno-
suppression, and it is the indication with the lowest level
of risk. Consideration of other indications as well may
be worthwhile in the future.
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